Trials / Conditions / Biliary Tract Carcinoma

Biliary Tract Carcinoma

29 registered clinical trials studyying Biliary Tract Carcinoma — 13 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044	Mayo Clinic	Phase 2
Not Yet Recruiting	Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Car NCT07099547	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 2
Not Yet Recruiting	A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC NCT07062328	Sun Yat-sen University	Phase 2
Not Yet Recruiting	Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC NCT06699459	Sir Run Run Shaw Hospital	Phase 2
Not Yet Recruiting	Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma NCT06530823	Eastern Hepatobiliary Surgery Hospital	Phase 2
Not Yet Recruiting	Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Car NCT06463548	Yunpeng Liu	N/A
Not Yet Recruiting	Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Pa NCT06430827	Ba Yi	Phase 2
Recruiting	Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcin NCT06168292	National Cancer Center, Korea	N/A
Recruiting	A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherap NCT06349044	Zhejiang Cancer Hospital	N/A
Recruiting	Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers NCT06048133	Nataliya Uboha	Phase 2
Suspended	SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma NCT06199882	Zhejiang Cancer Hospital	Phase 2
Unknown	Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction NCT06047990	Brno University Hospital	N/A
Not Yet Recruiting	Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma NCT05822453	Peking Union Medical College Hospital	Phase 2
Unknown	Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma NCT05845554	Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University	—
Recruiting	GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma NCT05668884	Fudan University	Phase 2
Recruiting	A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Maligna NCT05123482	AstraZeneca	Phase 1 / Phase 2
Terminated	A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma NCT04003896	Milton S. Hershey Medical Center	Phase 2
Unknown	A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma NCT05064852	Qilu Hospital of Shandong University	—
Unknown	GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC NCT05023109	Shanghai Zhongshan Hospital	Phase 2
Unknown	GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer NCT04979663	Fudan University	Phase 1 / Phase 2
Unknown	Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer NCT04984980	Fudan University	Phase 2
Completed	Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Ad NCT04924062	Merck Sharp & Dohme LLC	Phase 3
Terminated	A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior NCT04178460	Zai Lab (Shanghai) Co., Ltd.	Phase 1
Completed	Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Ad NCT04003636	Merck Sharp & Dohme LLC	Phase 3
Completed	Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960	Mayo Clinic	EARLY_Phase 1
Completed	A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer NCT03027284	Eli Lilly and Company	Phase 1
Withdrawn	A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer NCT02105350	University Health Network, Toronto	Phase 1
Active Not Recruiting	A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone NCT02151084	University Health Network, Toronto	Phase 2
Completed	Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas NCT00490399	Eli Lilly and Company	Phase 2